EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Avelumab + axitinib treatment in older patients with advanced renal cell carcinoma in Japan: Subgroup analyses of post‐marketing surveillance data by age

Mototsugu Oya iD, Taito Ito, Masashi Sato, Makiko Morita, Masahiro Kajita, Norio Nonomura iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.70186 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Mototsugu Oya und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Axitinib, Carcinoma, Renal Cell, Antibodies, Monoclonal, Humanized, Kidney Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945), Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Avelumab + axitinib was approved in Japan in December 2019 for the treatment of curatively unresectable or metastatic renal cell carcinoma (RCC) based on results from the JAVELIN Renal 101 trial. Materials and Methods To evaluate the safety and effectiveness of avelumab + axitinib in older patients in general clinical practice in Japan, an ad hoc analysis of data from post‐marketing surveillance (PMS) by age group was conducted.

Results

The analysis population included 328 patients who had received ≥1 dose of avelumab and were enrolled between December 2019 and May 2021. In total, 100 patients (30.5%) were aged ≤64 years, 130 (39.6%) were aged 65–74 years, and 98 (29.9%) were aged ≥75 years. Within these age groups, adverse drug reactions (ADRs) of safety specifications of any grade occurred in 46 (46.0%), 71 (54.6%), and 56 (57.1%), and of grade ≥3 in 13 (13.0%), 23 (17.7%), and 20 (20.4%), respectively. The most common ADRs of safety specifications across all age groups were thyroid dysfunction, infusion reactions, and hepatic function disorders. Median overall survival (OS) was not reached in any age group; 12‐month OS rates in patients aged ≤64, 65–74, or ≥75 years were 83.8%, 86.2%, and 80.0%, and objective response rates were 31.0%, 43.8%, and 30.6%, respectively.

Discussion

Analyses of PMS data show the safety and effectiveness of avelumab + axitinib across all age groups of patients with RCC in general clinical practice in Japan. The favorable benefit–risk profile was generally consistent with that observed in previous clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AxitinibCarcinoma, Renal CellAntibodies, Monoclonal, HumanizedKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansAgedMaleFemaleJapanProduct Surveillance, PostmarketingMiddle AgedAged, 80 and overAge Factors

Stichwörter der Autor:innen

checkpoint controlclinical cancer researchrenal cancertarget therapytyrosine kinase inhibitors

Substanzen

AxitinibavelumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Urology, Keio University School of Medicine, Tokyo, Japan.
  • Medical Department, Merck Biopharma Co., Ltd., Tokyo, Japan, an Affiliate of Merck KGaA, Darmstadt, Germany.
  • Research and Development, Merck Biopharma Co., Ltd., Tokyo, Japan, an Affiliate of Merck KGaA, Darmstadt, Germany.
  • Global Patient Safety Japan, Merck Biopharma Co., Ltd., Tokyo, Japan, an Affiliate of Merck KGaA, Darmstadt, Germany.
  • Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan.

ORCID-Profile: Mototsugu Oya, Norio Nonomura

Förderung

  • Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945)
  • Pfizer

Zitieren

APA

Oya, M., Ito, T., Sato, M., Morita, M., Kajita, M., & Nonomura, N. (2025). Avelumab + axitinib treatment in older patients with advanced renal cell carcinoma in Japan: Subgroup analyses of post‐marketing surveillance data by age. Cancer Medicine. https://doi.org/10.1002/cam4.70186

Vancouver

Oya M, Ito T, Sato M, Morita M, Kajita M, Nonomura N. Avelumab + axitinib treatment in older patients with advanced renal cell carcinoma in Japan: Subgroup analyses of post‐marketing surveillance data by age. Cancer Medicine. 2025. doi:10.1002/cam4.70186

BibTeX
@article{Oya2025,
  author = {Oya, Mototsugu and Ito, Taito and Sato, Masashi and Morita, Makiko and Kajita, Masahiro and Nonomura, Norio},
  title = {Avelumab + axitinib treatment in older patients with advanced renal cell carcinoma in Japan: Subgroup analyses of post‐marketing surveillance data by age},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70186}
}
Kostenlos starten →